Genentech meets street, IDPH also in line

Following the market close, DNA reported fourth quarter and FY EPS of $0.16 and $0.60, respectively, meeting the Street's consensus on both counts, exclusive of certain charges and changes in accounting treatment. DNA's earnings were aided by a 22 percent jump in annual revenues - to $1.74 billion from $1.42 billion in 1999 - primarily driven by a 23 percent gain in product sales to $1.28 billion from $1.04 billion. Sales of Rituxan rituximab, co-promoted by Idec (IDPH), were $444.1 million versus $279.4 million last year. DNA closed Thursday at $60.688, down $2.563. ...